	US 12,268,685 B2
	Dosing regimen for injectable cetirizine
Jie Du, Lansdale, PA (US)
Assigned to JDP THERAPEUTICS LLC, Deerfield, IL (US)
Filed by JDP THERAPEUTICS LLC, Deerfield, IL (US)
Filed on Oct. 18, 2024, as Appl. No. 18/919,625.
Application 18/919,625 is a continuation of application No. 18/520,024, filed on Nov. 27, 2023.
Application 18/520,024 is a continuation of application No. 16/656,656, filed on Oct. 18, 2019, abandoned.
Application 16/656,656 is a continuation of application No. 16/594,919, filed on Oct. 7, 2019, granted, now 11,253,513, issued on Feb. 22, 2022.
Prior Publication US 2025/0041289 A1, Feb. 6, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/495 (2006.01); A61K 9/00 (2006.01); A61P 17/04 (2006.01); A61P 37/08 (2006.01)

CPC A61K 31/495 (2013.01) [A61K 9/0019 (2013.01); A61P 17/04 (2018.01); A61P 37/08 (2018.01)]

10 Claims

1. A method of administering injectable cetirizine or levocetirizine to a human subject, comprising intravenously injecting the human subject in need thereof with an overdose of a maximum human daily clinical dose of the cetirizine or levocetirizine,

wherein the human subject is a child 6 months to 5 years and the maximum human daily clinical dose of cetirizine dihydrochloride is 2.5 mg; the human subject is a child 6 to 11 years and the maximum human daily clinical dose of cetirizine dihydrochloride is 5 to 10 mg; or the human subject is an adult of adolescent 12 years older and the maximum human daily clinical dose of cetirizine dihydrochloride is 10 mg,

wherein the overdose is no more than 14 times the maximum human daily clinical dose of the cetirizine or levocetirizine.